Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Arcadia Biosciences, Inc. (RKDA)

Arcadia Biosciences gets Nasdaq notice on $633,000 stockholders' equity shortfall

Negative Impact 4 of 5 legal/regulatory Written later

Arcadia Biosciences received a Nasdaq letter dated August 31, 2026, saying its stockholders' equity of $633,000 at June 30, 2026, was below the $2.5 million minimum for continued listing on the Nasdaq Capital Market. The company's common stock will continue to trade on the Nasdaq Capital Market for now, but the company must submit a compliance plan, and there is no assurance Nasdaq will accept it.

Key points

  • Reported stockholders' equity was $633,000 as of June 30, 2026, versus the $2.5 million minimum under Nasdaq Listing Rule 5550(b)(1).
  • The company does not meet Nasdaq's alternative market value or net income standards either.
  • The compliance plan is due to Nasdaq by October 15, 2026; if accepted, Nasdaq may grant up to 180 calendar days to show compliance.
  • If Nasdaq rejects the plan, the company may appeal to a Nasdaq Hearings Panel, which ordinarily stays any suspension or delisting action.

The filing

CompanyArcadia Biosciences, Inc. (RKDA)
Form8-K, current report
Filed with the SECSep 4, 2026, 4:05 PM ET
Accession number0001193125-26-383642

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.